EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation

Minjeong Nam iD, Mina Hur iD, Hanah Kim iD, Tae-Hwan Lee, Gun-Hyuk Lee, Sumi Yoon iD, Seungman Park, Sung Yong Kim, Mark Hong Lee

Journal of Clinical Medicine · 06.01.2023 · 12 (2) · 458

DOI: 10.3390/jcm12020458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.01.2023. Verfasst von Minjeong Nam und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Korea University Anam Hospital, Seoul 02841, Republic of Korea. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ABO incompatibility is not considered a contraindication for hematopoietic stem cell transplantation (HSCT). We hypothesized that recipient-derived isoagglutinin (RDI) levels could play a critical role in clinical outcomes. In this study, we compared clinical outcomes such as survival, GVHD, infection, relapse, transfusion, and engraftment, among ABO-compatible patients (ABOc), ABO-incompatible patients (ABOi) with low RDI, and ABOi patients with high RDI. The ABOi with high RDI group was defined as recipients with more than 1:16 RDI levels. We analyzed 103 recipients (ABOc, 53; ABOi with low RDI, 36; ABOi with high RDI, 14). The ABOi with high RDI group showed a decreased 1-year survival and increased acute GVHD grade IV and RBC transfusion (p = 0.017, 0.027, and 0.032, respectively). The ABOi with high RDI group was an independent risk factor for increased death, RBC transfusion, and poor platelet (PLT) engraftment (odds ratio (OR) = 3.20, p = 0.01; OR = 8.28, p = 0.02; OR = 0.18, p = 0.03, respectively). The ABOi with high RDI group showed significantly delayed PLT engraftment. In conclusion, this is the first study underscoring high RDI levels as a marker predicting unfavorable outcomes in ABOi HSCT.

Schlagwörter

Stichwörter der Autor:innen

RBC transfusiongraft-versus-host diseasehematopoietic stem cell transplantationplatelet engraftmentrecipient-derived isoagglutininsurvival

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Korea University Anam Hospital, Seoul 02841, Republic of Korea.
  • Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.
  • Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul 06973, Republic of Korea.
  • Department of Laboratory Medicine, National Cancer Center, Seoul 10408, Republic of Korea.
  • Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.

ORCID-Profile: Minjeong Nam, Mina Hur, Hanah Kim, Sumi Yoon

Zitieren

APA

Nam, M., Hur, M., Kim, H., Lee, T. H., Lee, G. H., Yoon, S., Park, S., Kim, S. Y., & Lee, M. H. (2023). Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation. Journal of Clinical Medicine, 12(2), 458. https://doi.org/10.3390/jcm12020458

Vancouver

Nam M, Hur M, Kim H, Lee TH, Lee GH, Yoon S, et al. Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation. Journal of Clinical Medicine. 2023;12(2):458. doi:10.3390/jcm12020458

BibTeX
@article{Nam2023,
  author = {Nam, Minjeong and Hur, Mina and Kim, Hanah and Lee, Tae-Hwan and Lee, Gun-Hyuk and Yoon, Sumi and Park, Seungman and Kim, Sung Yong and Lee, Mark Hong},
  title = {Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {2},
  pages = {458},
  doi = {10.3390/jcm12020458}
}
Kostenlos starten →